Please login to the form below

lebrikizumab

This page shows the latest lebrikizumab news and features for those working in and with pharma, biotech and healthcare.

Dermira craters as acne drug fails late-stage test

Also in its pipeline is an injectable drug for atopic dermatitis - I L-13 inhibitor lebrikizumab - which was developed by Roche and licensed to Dermira in a deal valued at up ... That programme is in mid-stage clinical testing. Even if it successfully

Latest news

Setback for AZ as tralokinumab flunks asthma trial

The failure of tralokinumab hasn’t come out of the blue, as another trial (STRATOS 1) also failed to hit the mark, and other IL-13 inhibitors - including Roche’s lebrikizumab
Roche out-licenses lebrikizumab rights to Dermira

Roche has opted to out-license the bulk of the rights to its IL-13 inhibitor lebrikizumab to dermatology company Dermira in a deal valued at up to $1.4bn. ... The deal includes rights to lebrikizumab for atopic dermatitis and all other indications with
AZ trial adds to pessimism about anti-IL-13 asthma drugs

It looks increasingly like a lost cause as AZ already reported disappointing phase IIb data with tralokinumab, and last year Roche reported disappointing results with its anti-IL-13 candidate lebrikizumab,
Teva gets EU nod for severe asthma drug Cinqaero

13 inhibitor lebrikizumab.
Roche shares slip as profits miss expectations

Aside with atezolizumab, Roche is also looking ahead to possible launches for multiple sclerosis candidate ocrelizumab - also due for filing shortly - as well as asthma drug lebrikizumab.

More from news
Approximately 2 fully matching, plus 10 partially matching documents found.

Latest Intelligence

Pharma deals during August 2014

This brings a much needed boost to its respiratory portfolio, which currently consists of Pulmozyme (cystic fibrosis) and Xolair (severe asthma) and products in clinical development, eg lebrikizumab (severe asthma).

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Project/ Events Manager – Medical Education and Events Agency: Salary TBC

Senior Medical Writer: Great salary and benefits

Account Director, Healthcare Marketing Agency: Salary TBC

AD – Corporate Comms/ Public Affairs/ B2B – Healthcare Focus: Salary TBC

Senior Medical Writer: Up to £50, 000 with Benefits

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Digital Account Director: Salary TBC

Editorial Assistant Medical Education Agency: £25, 000 - £26, 000

Account Director, Medical Education: Salary TBC

Account/ Project Director – Medical Affairs – Surrey: Salary TBC

Senior Planner – Healthcare Advertising – New Role: Salary TBC

Senior Medical Writer: Salary TBC

PR Director – Health & Wellbeing – Mat Cover (4 days a week)...: Salary TBC

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Project Manager/ Account Manager: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

2019: CRISPR and therapeutic gene editing comes of age: Can gene-editing deliver safe and effective therapeutics for patients with intractable diseases?...
The 10-year Web Challenge: Understanding your users’ needs is more critical online today than ever. A site should mould itself around these insights, deliver those needs quickly, efficiently and with plenty of white space....
Downloadable Pack: Understanding Multiple Sclerosis: Inside this downloadable pack, you’ll find a wealth of exclusive information on the way multiple sclerosis is commonly treated today. As well as areas of continuous improvement for the industry....